NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 143 filers reported holding NEKTAR THERAPEUTICS in Q3 2013. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $12,052 | -92.1% | 20,952 | -56.0% | 0.00% | -90.9% |
| Q3 2022 | $152,000 | +1281.8% | 47,596 | +1537.9% | 0.01% | +1000.0% |
| Q2 2022 | $11,000 | +1000.0% | 2,906 | +1353.0% | 0.00% | – |
| Q1 2022 | $1,000 | -92.9% | 200 | -74.9% | 0.00% | -100.0% |
| Q3 2021 | $14,000 | -60.0% | 797 | -47.8% | 0.00% | -80.0% |
| Q2 2020 | $35,000 | -82.7% | 1,528 | -83.7% | 0.01% | -75.0% |
| Q4 2019 | $202,000 | -76.8% | 9,363 | -47.4% | 0.02% | -66.1% |
| Q2 2018 | $869,000 | +219.5% | 17,813 | +12.2% | 0.06% | +96.7% |
| Q3 2016 | $272,000 | -62.7% | 15,882 | -73.7% | 0.03% | -70.0% |
| Q3 2014 | $729,000 | +40.2% | 60,448 | +48.8% | 0.10% | +22.0% |
| Q2 2014 | $520,000 | +51900.0% | 40,637 | +40537.0% | 0.08% | – |
| Q4 2013 | $1,000 | -97.9% | 100 | -97.8% | 0.00% | -100.0% |
| Q3 2013 | $48,000 | – | 4,600 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |